drugset
drugset / Trial / NCT06063473

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris

NCT06063473 ↗

Phase 1 Completed 762 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

To demonstrate therapeutic equivalence and safety of Trifarotene cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and AKLIEF® cream in the treatment of acne vulgaris

Timeline

Start
2023-02-22
Primary completion
2023-07-13
Completion
2023-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Trifarotene Small molecule 0.005 % Topical

Indications

acne